PE20080970A1 - Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos - Google Patents

Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos

Info

Publication number: PE20080970A1
Authority: PE; Peru
Prior art keywords: quinazolin; piperidin; oxo; methyl; alkyl
Prior art date: 2006-09-26

Application number

PE2007001298A

Other languages

English (en)

Spanish (es)

Inventor

George W Muller

Hon-Wah Man

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-26

Filing date

2007-09-26

Publication date

2008-07-19

2007-09-26 Application filed by Celgene Corp filed Critical Celgene Corp

2008-07-19 Publication of PE20080970A1 publication Critical patent/PE20080970A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Virology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychology (AREA)
Epidemiology (AREA)

PE2007001298A 2006-09-26 2007-09-26 Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos PE20080970A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US84747106P	2006-09-26	2006-09-26

Publications (1)

Publication Number	Publication Date
PE20080970A1 true PE20080970A1 (es)	2008-07-19

Family

ID=39230813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2007001298A PE20080970A1 (es)	2006-09-26	2007-09-26	Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos

Country Status (33)

Country	Link
US (4)	US7635700B2 (zh)
EP (5)	EP2428513B1 (zh)
JP (4)	JP5388854B2 (zh)
KR (1)	KR101414786B1 (zh)
CN (6)	CN104910133A (zh)
AR (2)	AR063015A1 (zh)
AT (1)	ATE555104T1 (zh)
CA (1)	CA2663731C (zh)
CL (1)	CL2007002752A1 (zh)
CO (1)	CO6160323A2 (zh)
CR (1)	CR10712A (zh)
CY (3)	CY1112860T1 (zh)
DK (4)	DK2420498T3 (zh)
ES (4)	ES2634915T3 (zh)
HR (4)	HRP20120447T1 (zh)
HU (3)	HUE026827T2 (zh)
IL (3)	IL197716A (zh)
LT (2)	LT2428513T (zh)
ME (4)	ME01421B (zh)
MX (1)	MX2009003038A (zh)
MY (1)	MY150699A (zh)
NI (1)	NI200900040A (zh)
NZ (1)	NZ575830A (zh)
PE (1)	PE20080970A1 (zh)
PL (4)	PL2066656T3 (zh)
PT (3)	PT2428513T (zh)
RS (3)	RS54607B1 (zh)
RU (3)	RU2463298C2 (zh)
SI (4)	SI2420497T1 (zh)
TW (2)	TWI522351B (zh)
UA (1)	UA94964C2 (zh)
WO (1)	WO2008039489A2 (zh)
ZA (1)	ZA200901950B (zh)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8877780B2 (en) *	2006-08-30	2014-11-04	Celgene Corporation	5-substituted isoindoline compounds
ME01421B (me) *	2006-09-26	2013-12-20	Celgene Corp	5-supstituisani derivati kinazolinona kao protivtumorska sredstva
EP2200999B1 (en)	2007-09-26	2014-08-13	Celgene Corporation	6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US8354417B2 (en) *	2007-09-26	2013-01-15	Celgene Corporation	Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same
US7786171B2 (en)	2008-04-04	2010-08-31	Abbott Laboratories	Amide derivatives as positive allosteric modulators and methods of use thereof
WO2009148623A2 (en)	2008-06-05	2009-12-10	Stc.Unm	Methods and related compositions for the treatment of cancer
US20100160368A1 (en)	2008-08-18	2010-06-24	Gregory Jefferson J	Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
DK2378876T3 (en)	2008-12-19	2019-03-11	Medicis Pharmaceutical Corp	IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
EP2433124B1 (en) *	2009-05-19	2017-03-01	Vivia Biotech S.L.	Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2010137547A1 (ja)	2009-05-25	2010-12-02	国立大学法人東京工業大学	中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
ES2653313T3 (es)	2009-07-13	2018-02-06	Medicis Pharmaceutical Corporation	Formulaciones de imiquimod con concentración de dosificación menor y regímenes de dosificación cortos para el tratamiento de verrugas genitales y perianales
CN101913846B (zh) *	2010-08-11	2012-05-23	昆明理工大学	一种用煤泥磷石膏冶金废渣合成陶粒的方法
SG192947A1 (en) *	2011-03-11	2013-09-30	Celgene Corp	Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
AU2012229279B2 (en) *	2011-03-11	2017-06-22	Celgene Corporation	Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
US9090585B2 (en)	2011-03-28	2015-07-28	Deuterx, Llc	2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
EP2702410A2 (en)	2011-04-29	2014-03-05	Celgene Corporation	Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
ES2872967T3 (es)	2012-06-29	2021-11-03	Celgene Corp	Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
ES2814952T3 (es)	2012-09-04	2021-03-29	Celgene Corp	Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
JP6306592B2 (ja) *	2012-09-10	2018-04-04	セルジーンコーポレイション	局所進行乳癌を治療するための方法
WO2014110558A1 (en) *	2013-01-14	2014-07-17	Deuterx, Llc	3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
AU2014236597A1 (en)	2013-03-14	2015-09-24	Deuterx, Llc	3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives
KR102240356B1 (ko) *	2013-04-17	2021-04-14	시그날 파마소티칼 엘엘씨	Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
HRP20171535T1 (hr)	2013-05-01	2017-11-17	Celgene Corporation	Sinteza 3-(5-amino-2-metil-4-oksokinazolin-3(4h)-il)piperidin-2,6-diona
US9119854B2 (en) *	2013-05-03	2015-09-01	Celgene Corporation	Methods for treating cancer using combination therapy
UA117141C2 (uk)	2013-10-08	2018-06-25	Селджин Корпорейшн	Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
CN103645259B (zh) *	2013-12-12	2015-03-11	深圳海王药业有限公司	一种同时测定泊马度胺及其有关物质的方法
TW201540323A (zh)	2014-01-15	2015-11-01	Celgene Corp	３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
JP6615791B2 (ja)	2014-06-05	2019-12-04	バイエル・クロップサイエンス・アクチェンゲゼルシャフト	殺虫剤としての二環式化合物
EP3160486B1 (en)	2014-06-27	2020-11-18	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
EA201790439A1 (ru)	2014-08-22	2017-07-31	Селджин Корпорейшн	Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
TW201642857A (zh)	2015-04-06	2016-12-16	西建公司	以組合療法治療肝細胞癌
MX2018000216A (es)	2015-07-02	2018-05-22	Celgene Corp	Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos.
US9809603B1 (en)	2015-08-18	2017-11-07	Deuterx, Llc	Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10064863B2 (en)	2015-08-27	2018-09-04	Celgene Corporation	Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
DK3357513T3 (da) *	2015-09-29	2023-11-27	Kangpu Biopharmaceuticals Inc	Farmaceutisk sammensætning og anvendelse deraf
BR112018010964A2 (pt)	2015-12-02	2018-12-04	Celgene Corp	terapia de ciclo usando 3-(5-amino-2-methil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
US10830762B2 (en)	2015-12-28	2020-11-10	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
DK3404024T3 (da) *	2016-01-14	2021-01-11	Kangpu Biopharmaceuticals Inc	Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser
ES2990061T3 (es)	2016-05-10	2024-11-28	C4 Therapeutics Inc	Degronímeros espirocíclicos para la degradación de proteínas diana
ES2989988T3 (es)	2016-05-10	2024-11-28	C4 Therapeutics Inc	Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
EP3455219A4 (en)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
PL3527210T3 (pl)	2016-12-16	2021-11-29	Kangpu Biopharmaceuticals, Ltd.	Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania
CA3053805C (en)	2017-02-13	2020-06-30	Kangpu Biopharmaceuticals, Ltd.	Combination treating prostate cancer, pharmaceutical composition and treatment method
US20180258064A1 (en)	2017-03-07	2018-09-13	Celgene Corporation	Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
KR102014478B1 (ko) *	2017-05-12	2019-08-26	한국화학연구원	신규한 피페리딘-2,6-디온 유도체 및 이의 용도
WO2018237026A1 (en)	2017-06-20	2018-12-27	C4 Therapeutics, Inc.	N/o-linked degrons and degronimers for protein degradation
CA3072735A1 (en)	2017-08-21	2019-02-28	Celgene Corporation	Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
WO2019043214A1 (en)	2017-09-04	2019-03-07	F. Hoffmann-La Roche Ag	glutarimide
EP3679027A1 (en)	2017-09-04	2020-07-15	C4 Therapeutics, Inc.	Dihydrobenzimidazolones
EP3679028A1 (en)	2017-09-04	2020-07-15	C4 Therapeutics, Inc.	Dihydroquinolinones
WO2019099868A2 (en)	2017-11-16	2019-05-23	C4 Therapeutics, Inc.	Degraders and degrons for targeted protein degradation
CN111902403B (zh)	2018-01-17	2024-05-17	奥里吉恩发现科技有限公司	作为抗癌剂的取代的亚炔基化合物
SG11202007495SA (en)	2018-02-21	2020-09-29	Celgene Corp	Bcma-binding antibodies and uses thereof
KR20210018199A (ko)	2018-03-26	2021-02-17	씨4 테라퓨틱스, 인코포레이티드	이카로스의 분해를 위한 세레블론 결합제
CN112312904B (zh)	2018-04-16	2025-01-07	C4医药公司	螺环化合物
EP3578561A1 (en)	2018-06-04	2019-12-11	F. Hoffmann-La Roche AG	Spiro compounds
MX2021005366A (es)	2018-11-08	2021-09-10	Juno Therapeutics Inc	Metodos y combinaciones para el tratamiento y modulacion de celulas t.
EP3897631A4 (en)	2018-12-20	2022-11-23	C4 Therapeutics, Inc.	TARGETED PROTEIN BREAKDOWN
EP3935050B1 (en)	2019-03-06	2024-10-02	C4 Therapeutics, Inc.	Heterocyclic compounds for medical treatment
MA55628A (fr)	2019-04-12	2022-02-16	C4 Therapeutics Inc	Agents de dégradation tricycliques d'ikaros et d'aiolos
JP7760167B2 (ja)	2019-11-27	2025-10-27	キャプターセラピューティクスエス．エー．	セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法
WO2021105334A1 (en)	2019-11-27	2021-06-03	Captor Therapeutics S.A.	Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
US11807620B2 (en)	2020-02-21	2023-11-07	Plexium, Inc.	Quinazolinone compounds and related compounds
CN115916191A (zh)	2020-06-25	2023-04-04	新基公司	用组合疗法治疗癌症的方法
JP2023535453A (ja) *	2020-07-24	2023-08-17	イニファーム，インク．	キナゾリノンｈｓｄ１７ｂ１３阻害剤とその使用
CN116457344A (zh)	2020-08-03	2023-07-18	凯普托尔治疗学股份有限公司	低分子量蛋白质降解剂及其应用
EP4198030A4 (en) *	2020-08-14	2024-01-10	Shanghaitech University	Immunoregulatory compound and antitumor application thereof
MX2023005550A (es)	2020-11-13	2023-07-18	Inipharm Inc	Inhibidores de diclorofenol hsd17b13 y usos de los mismos.
WO2022146151A1 (en)	2020-12-30	2022-07-07	Captor Therapeutics S.A.	Novel compounds which bind to cereblon, and methods of use thereof
WO2022255890A1 (en)	2021-06-01	2022-12-08	Captor Therapeutics S.A.	Compounds which bind to cereblon, and use thereof
WO2022255889A1 (en)	2021-06-01	2022-12-08	Captor Therapeutics S.A.	Compounds which bind to cereblon, and use thereof
CN116589445A (zh) *	2022-02-14	2023-08-15	标新生物医药科技(上海)有限公司	基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用
AU2023283735A1 (en)	2022-06-06	2024-10-31	C4 Therapeutics, Inc.	Bicyclic-substituted glutarimide cereblon binders
WO2024167423A1 (en)	2023-02-07	2024-08-15	Captor Therapeutics S.A.	Gspt1 degrader compounds
CN116789530B (zh) *	2023-05-16	2025-12-19	杭州师范大学	一种紫苏醇酚类衍生物及其制备方法和应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1997563A (en) *	1929-05-31	1935-04-09	Karmazin Engineering Company	Method of making heat radiators
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en)	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US5001116A (en)	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
WO1995003009A1 (en)	1993-07-22	1995-02-02	Oculex Pharmaceuticals, Inc.	Method of treatment of macular degeneration
US5770589A (en)	1993-07-27	1998-06-23	The University Of Sydney	Treatment of macular degeneration
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274549B (it)	1995-05-23	1997-07-17	Indena Spa	Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en)	1996-01-25	1998-09-01	National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology	Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
CA2560523C (en) *	1996-07-24	2011-09-20	Celgene Corporation	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6015803A (en)	1998-05-04	2000-01-18	Wirostko; Emil	Antibiotic treatment of age-related macular degeneration
US6225348B1 (en)	1998-08-20	2001-05-01	Alfred W. Paulsen	Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en)	1998-09-03	1999-12-14	Protein Technologies International, Inc.	Method for inhibiting or reducing the risk of macular degeneration
US7182953B2 (en)	1999-12-15	2007-02-27	Celgene Corporation	Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
PL366311A1 (en)	2000-12-11	2005-01-24	Tularik Inc.	Cxcr3 antagonists
WO2003007955A2 (en)	2001-07-20	2003-01-30	Cancer Research Technology Limited	Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003041326A2 (en)	2001-11-09	2003-05-15	Matsushita Electric Industrial Co., Ltd.	Moving picture coding method and apparatus
FR2837201A1 (fr) *	2002-03-18	2003-09-19	Servier Lab	Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7393862B2 (en)	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en)	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en)	2002-10-31	2004-05-13	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en)	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050024328A1 (en)	2003-07-23	2005-02-03	Graham Oldfield	Control area selection in a computing device with a graphical user interface
US20050100529A1 (en)	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1684758A4 (en)	2003-11-06	2009-02-18	Celgene Corp	METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
JP2007511496A (ja)	2003-11-14	2007-05-10	メルクシャープエンドドームリミテッド	バニロイド−１受容体（ｖｒ１）の機能を調節する二環式ピリミジン−４−（３ｈ）−オン類並びにその類似体及び誘導体
BRPI0417186A (pt)	2003-12-02	2007-03-06	Celgene Corp	método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
US20050143344A1 (en)	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
AU2005226649B2 (en)	2004-03-22	2010-04-29	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en)	2004-04-01	2005-10-06	Zeldis Jerome B	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
EP1755600A2 (en)	2004-04-23	2007-02-28	Celgene Corporation	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
MX2007005570A (es)	2004-11-12	2007-07-09	Celgene Corp	Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
BRPI0518282A2 (pt)	2004-11-23	2008-11-11	Celgene Corp	uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
GB0506147D0 (en)	2005-03-24	2005-05-04	Merck Sharp & Dohme	Therapeutic agents
EP1881988A1 (en)	2005-05-11	2008-01-30	MERCK SHARP & DOHME LTD.	2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
GB0509573D0 (en)	2005-05-11	2005-06-15	Merck Sharp & Dohme	Therapeutic compounds
WO2007113558A2 (en)	2006-04-05	2007-10-11	Astrazeneca Ab	Quinazolinone derivatives having b-raf inhibitory activity
CN101415689A (zh)	2006-04-05	2009-04-22	阿斯利康(瑞典)有限公司	具有抗癌活性的经取代的喹唑啉
CN101421253A (zh)	2006-04-18	2009-04-29	阿斯利康(瑞典)有限公司	喹唑啉-4-酮衍生物、其制备方法及含有它们的药用组合物
ME01421B (me) *	2006-09-26	2013-12-20	Celgene Corp	5-supstituisani derivati kinazolinona kao protivtumorska sredstva
EP2200999B1 (en)	2007-09-26	2014-08-13	Celgene Corporation	6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2011047129A1 (en)	2009-10-15	2011-04-21	Southern Research Institute	Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
WO2012027065A2 (en)	2010-08-27	2012-03-01	Celgene Corporation	Combination therapy for treatment of disease
WO2012066330A1 (en)	2010-11-17	2012-05-24	Heptares Therapeutics Limited	Compounds useful as a2a receptor inhibitors
US20120302605A1 (en)	2010-11-18	2012-11-29	Deuteria Pharmaceuticals, Llc	3-deutero-pomalidomide
SG192947A1 (en)	2011-03-11	2013-09-30	Celgene Corp	Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
AU2012229279B2 (en)	2011-03-11	2017-06-22	Celgene Corporation	Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP2702410A2 (en)	2011-04-29	2014-03-05	Celgene Corporation	Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP2802877A1 (en)	2012-01-13	2014-11-19	Celgene Corporation	Biomarkers for the treatment of hepatocellular carcinoma
ES2872967T3 (es)	2012-06-29	2021-11-03	Celgene Corp	Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9587281B2 (en)	2012-08-14	2017-03-07	Celgene Corporation	Cereblon isoforms and their use as biomarkers for therapeutic treatment
ES2814952T3 (es)	2012-09-04	2021-03-29	Celgene Corp	Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos
JP6306592B2 (ja)	2012-09-10	2018-04-04	セルジーンコーポレイション	局所進行乳癌を治療するための方法
WO2014110558A1 (en)	2013-01-14	2014-07-17	Deuterx, Llc	3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
AU2014235273A1 (en)	2013-03-14	2015-07-09	Celgene Corporation	Treatment of psoriatic arthritis using apremilast
KR102223060B1 (ko)	2013-04-17	2021-03-05	시그날 파마소티칼 엘엘씨	암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법
KR102240356B1 (ko)	2013-04-17	2021-04-14	시그날 파마소티칼 엘엘씨	Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
CA2909579A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
HRP20171535T1 (hr)	2013-05-01	2017-11-17	Celgene Corporation	Sinteza 3-(5-amino-2-metil-4-oksokinazolin-3(4h)-il)piperidin-2,6-diona
US9119854B2 (en)	2013-05-03	2015-09-01	Celgene Corporation	Methods for treating cancer using combination therapy
ES2903155T3 (es)	2013-12-06	2022-03-31	Celgene Corp	Métodos para determinar la eficacia del fármaco para el tratamiento de linfoma difuso de células B grandes, mieloma múltiple y cánceres mieloides
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
TW201540323A (zh)	2014-01-15	2015-11-01	Celgene Corp	３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
WO2015107196A1 (en)	2014-01-20	2015-07-23	Institut Curie	Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
US20150258082A1 (en)	2014-03-14	2015-09-17	Francesco Parlati	Combination therapy with glutaminase inhibitors
WO2015160845A2 (en)	2014-04-14	2015-10-22	Arvinas, Inc.	Imide-based modulators of proteolysis and associated methods of use
EP3160486B1 (en)	2014-06-27	2020-11-18	Celgene Corporation	Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
US20170128448A1 (en)	2014-07-11	2017-05-11	Celgene Corporation	Combination therapy for cancer
WO2016014890A1 (en)	2014-07-24	2016-01-28	Calithera Biosciences, Inc.	Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en)	2014-08-07	2016-02-11	Calithera Biosciences, Inc.	Crystal forms of glutaminase inhibitors
WO2016025686A1 (en)	2014-08-15	2016-02-18	Celgene Corporation	Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
EP3207151A4 (en)	2014-10-13	2018-07-04	Celgene Corporation	Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
WO2016105518A1 (en)	2014-12-23	2016-06-30	Dana-Farber Cancer Institute, Inc.	Methods to induce targeted protein degradation through bifunctional molecules
US9717745B2 (en)	2015-03-19	2017-08-01	Zhejiang DTRM Biopharma Co. Ltd.	Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2016153948A1 (en)	2015-03-20	2016-09-29	Deuterx, Llc	Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
US10450299B2 (en)	2015-03-25	2019-10-22	Centre National De La Recherche Scientifique (Cnrs)	Substituted quinazoline derivatives as DNA methyltransferase inhibitors
TW201642857A (zh)	2015-04-06	2016-12-16	西建公司	以組合療法治療肝細胞癌

2007
- 2007-09-25 ME MEP-2012-60A patent/ME01421B/me unknown
- 2007-09-25 SI SI200731756T patent/SI2420497T1/sl unknown
- 2007-09-25 ME MEP-2017-159A patent/ME02829B/me unknown
- 2007-09-25 CL CL200702752A patent/CL2007002752A1/es unknown
- 2007-09-25 CN CN201510163088.3A patent/CN104910133A/zh active Pending
- 2007-09-25 CN CN201710560709.0A patent/CN107445940A/zh active Pending
- 2007-09-25 UA UAA200904043A patent/UA94964C2/ru unknown
- 2007-09-25 EP EP11174059.3A patent/EP2428513B1/en active Active
- 2007-09-25 CA CA2663731A patent/CA2663731C/en not_active Expired - Fee Related
- 2007-09-25 PL PL07838876T patent/PL2066656T3/pl unknown
- 2007-09-25 MX MX2009003038A patent/MX2009003038A/es active IP Right Grant
- 2007-09-25 PL PL11174059T patent/PL2428513T3/pl unknown
- 2007-09-25 EP EP11174056.9A patent/EP2420498B1/en active Active
- 2007-09-25 LT LTEP11174059.3T patent/LT2428513T/lt unknown
- 2007-09-25 SI SI200731950T patent/SI2420498T1/sl unknown
- 2007-09-25 ME MEP-2017-152A patent/ME02890B/me unknown
- 2007-09-25 SI SI200730915T patent/SI2066656T1/sl unknown
- 2007-09-25 HR HRP20120447TT patent/HRP20120447T1/hr unknown
- 2007-09-25 LT LTEP11174056.9T patent/LT2420498T/lt unknown
- 2007-09-25 RS RS20160160A patent/RS54607B1/sr unknown
- 2007-09-25 MY MYPI20091187 patent/MY150699A/en unknown
- 2007-09-25 NZ NZ575830A patent/NZ575830A/en unknown
- 2007-09-25 DK DK11174056.9T patent/DK2420498T3/en active
- 2007-09-25 RU RU2009115653/04A patent/RU2463298C2/ru active
- 2007-09-25 ZA ZA200901950A patent/ZA200901950B/xx unknown
- 2007-09-25 HU HUE11174055A patent/HUE026827T2/en unknown
- 2007-09-25 CN CN2012103629552A patent/CN102898416A/zh active Pending
- 2007-09-25 DK DK11174059.3T patent/DK2428513T3/en active
- 2007-09-25 SI SI200731953T patent/SI2428513T1/sl unknown
- 2007-09-25 WO PCT/US2007/020765 patent/WO2008039489A2/en not_active Ceased
- 2007-09-25 EP EP17165492.4A patent/EP3239144A1/en not_active Withdrawn
- 2007-09-25 HU HUE11174056A patent/HUE035308T2/en unknown
- 2007-09-25 CN CN201510162174.2A patent/CN105017212A/zh active Pending
- 2007-09-25 PT PT111740593T patent/PT2428513T/pt unknown
- 2007-09-25 PT PT111740569T patent/PT2420498T/pt unknown
- 2007-09-25 ES ES11174059.3T patent/ES2634915T3/es active Active
- 2007-09-25 ES ES11174055.1T patent/ES2564935T3/es active Active
- 2007-09-25 JP JP2009530406A patent/JP5388854B2/ja not_active Expired - Fee Related
- 2007-09-25 PL PL11174056T patent/PL2420498T3/pl unknown
- 2007-09-25 DK DK11174055.1T patent/DK2420497T3/en active
- 2007-09-25 AT AT07838876T patent/ATE555104T1/de active
- 2007-09-25 RS RS20170707A patent/RS56279B1/sr unknown
- 2007-09-25 EP EP07838876A patent/EP2066656B1/en active Active
- 2007-09-25 CN CN201510163104.9A patent/CN104876908A/zh active Pending
- 2007-09-25 ME MEP-2016-47A patent/ME02420B/me unknown
- 2007-09-25 KR KR1020097008299A patent/KR101414786B1/ko not_active Expired - Fee Related
- 2007-09-25 ES ES07838876T patent/ES2385680T3/es active Active
- 2007-09-25 PL PL11174055T patent/PL2420497T3/pl unknown
- 2007-09-25 HU HUE11174059A patent/HUE035389T2/en unknown
- 2007-09-25 EP EP11174055.1A patent/EP2420497B1/en active Active
- 2007-09-25 PT PT07838876T patent/PT2066656E/pt unknown
- 2007-09-25 RS RS20120259A patent/RS52349B/sr unknown
- 2007-09-25 DK DK07838876.6T patent/DK2066656T3/da active
- 2007-09-25 CN CNA2007800426159A patent/CN101535291A/zh active Pending
- 2007-09-25 ES ES11174056.9T patent/ES2633818T3/es active Active
- 2007-09-26 TW TW102116418A patent/TWI522351B/zh not_active IP Right Cessation
- 2007-09-26 TW TW096135832A patent/TWI399372B/zh not_active IP Right Cessation
- 2007-09-26 AR ARP070104264A patent/AR063015A1/es active IP Right Grant
- 2007-09-26 US US11/904,551 patent/US7635700B2/en active Active
- 2007-09-26 PE PE2007001298A patent/PE20080970A1/es active IP Right Grant
2009
- 2009-03-19 IL IL197716A patent/IL197716A/en active IP Right Grant
- 2009-03-25 NI NI200900040A patent/NI200900040A/es unknown
- 2009-04-14 CR CR10712A patent/CR10712A/es unknown
- 2009-04-23 CO CO09041135A patent/CO6160323A2/es unknown
- 2009-12-11 US US12/636,651 patent/US8921385B2/en active Active
2012
- 2012-06-13 CY CY20121100536T patent/CY1112860T1/el unknown
- 2012-06-29 RU RU2012127334A patent/RU2617989C2/ru active
2013
- 2013-08-18 IL IL228017A patent/IL228017A/en active IP Right Grant
- 2013-10-08 JP JP2013210802A patent/JP5901599B2/ja not_active Expired - Fee Related
2014
- 2014-11-24 US US14/552,337 patent/US9732064B2/en active Active
2015
- 2015-11-06 JP JP2015218025A patent/JP6133383B2/ja not_active Expired - Fee Related
2016
- 2016-03-14 HR HRP20160266TT patent/HRP20160266T1/hr unknown
- 2016-07-12 AR ARP160102114A patent/AR105340A2/es unknown
2017
- 2017-02-28 IL IL250847A patent/IL250847A0/en unknown
- 2017-04-18 RU RU2017113360A patent/RU2017113360A/ru not_active Application Discontinuation
- 2017-04-19 JP JP2017082496A patent/JP2017165744A/ja not_active Ceased
- 2017-07-07 US US15/644,119 patent/US20170369471A1/en not_active Abandoned
- 2017-07-17 HR HRP20171093TT patent/HRP20171093T1/hr unknown
- 2017-07-18 HR HRP20171106TT patent/HRP20171106T1/hr unknown
- 2017-07-20 CY CY20171100778T patent/CY1119248T1/el unknown
- 2017-08-02 CY CY20171100831T patent/CY1119176T1/el unknown

Also Published As

Publication number	Publication date
HUE035308T2 (en)	2018-05-02
ES2385680T3 (es)	2012-07-30
HUE035389T2 (en)	2018-05-02
AR105340A2 (es)	2017-09-27
TWI522351B (zh)	2016-02-21
HK1167397A1 (zh)	2012-11-30
CN107445940A (zh)	2017-12-08
IL197716A0 (en)	2009-12-24
RU2017113360A3 (zh)	2018-10-18
TW200823192A (en)	2008-06-01
HRP20171093T1 (hr)	2017-10-06
EP2066656A2 (en)	2009-06-10
HRP20171106T1 (hr)	2017-10-06
SI2428513T1 (sl)	2017-10-30
MY150699A (en)	2014-02-28
TW201335147A (zh)	2013-09-01
CY1119248T1 (el)	2018-02-14
CY1119176T1 (el)	2018-02-14
HRP20120447T1 (hr)	2012-06-30
DK2428513T3 (en)	2017-08-21
JP2016053066A (ja)	2016-04-14
DK2420498T3 (en)	2017-08-14
PL2420498T3 (pl)	2017-10-31
PT2428513T (pt)	2017-08-28
PT2066656E (pt)	2012-06-28
RS52349B (sr)	2012-12-31
ME02420B (me)	2016-09-20
NI200900040A (es)	2010-02-01
ATE555104T1 (de)	2012-05-15
EP2420498B1 (en)	2017-05-31
US7635700B2 (en)	2009-12-22
SI2066656T1 (sl)	2012-06-29
RU2617989C2 (ru)	2017-05-02
US20080161328A1 (en)	2008-07-03
CY1112860T1 (el)	2016-04-13
IL250847A0 (en)	2017-04-30
CN104876908A (zh)	2015-09-02
US20170369471A1 (en)	2017-12-28
PL2420497T3 (pl)	2016-06-30
US20100093774A1 (en)	2010-04-15
LT2428513T (lt)	2017-10-25
HRP20160266T1 (hr)	2016-04-08
IL228017A0 (en)	2013-09-30
CA2663731C (en)	2015-05-19
CN104910133A (zh)	2015-09-16
CN101535291A (zh)	2009-09-16
EP2428513A1 (en)	2012-03-14
JP6133383B2 (ja)	2017-05-24
UA94964C2 (ru)	2011-06-25
ES2564935T3 (es)	2016-03-30
CR10712A (es)	2009-05-13
JP5901599B2 (ja)	2016-04-13
IL197716A (en)	2013-08-29
JP2010504973A (ja)	2010-02-18
IL228017A (en)	2017-03-30
CN102898416A (zh)	2013-01-30
JP2017165744A (ja)	2017-09-21
PL2428513T3 (pl)	2017-10-31
US9732064B2 (en)	2017-08-15
EP2420497B1 (en)	2015-12-16
WO2008039489A2 (en)	2008-04-03
SI2420498T1 (sl)	2017-12-29
RS54607B1 (sr)	2016-08-31
US20150080419A1 (en)	2015-03-19
ZA200901950B (en)	2010-06-30
EP2420498A1 (en)	2012-02-22
SI2420497T1 (sl)	2016-04-29
MX2009003038A (es)	2009-04-15
CN105017212A (zh)	2015-11-04
PT2420498T (pt)	2017-08-01
KR101414786B1 (ko)	2014-07-03
CO6160323A2 (es)	2010-05-20
HUE026827T2 (en)	2016-07-28
ES2634915T3 (es)	2017-09-29
ME02890B (me)	2018-04-20
RS56279B1 (sr)	2017-12-29
ES2633818T3 (es)	2017-09-25
LT2420498T (lt)	2017-10-25
RU2009115653A (ru)	2010-11-10
TWI399372B (zh)	2013-06-21
ME01421B (me)	2013-12-20
EP2420497A1 (en)	2012-02-22
EP3239144A1 (en)	2017-11-01
JP2014028850A (ja)	2014-02-13
RU2012127334A (ru)	2014-01-10
KR20090061061A (ko)	2009-06-15
NZ575830A (en)	2012-03-30
RU2463298C2 (ru)	2012-10-10
EP2428513B1 (en)	2017-05-31
DK2420497T3 (en)	2016-03-07
AR063015A1 (es)	2008-12-23
PL2066656T3 (pl)	2012-09-28
EP2066656B1 (en)	2012-04-25
CL2007002752A1 (es)	2008-07-11
ME02829B (me)	2018-01-20
DK2066656T3 (da)	2012-05-21
RU2017113360A (ru)	2018-10-18
WO2008039489A3 (en)	2008-08-28
US8921385B2 (en)	2014-12-30
CA2663731A1 (en)	2008-04-03
JP5388854B2 (ja)	2014-01-15

Publication	Publication Date	Title
PE20080970A1 (es)	2008-07-19	Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos
PE20060857A1 (es)	2006-09-02	Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20120690A1 (es)	2012-06-08	Derivados de 5-fluoropirimidinona
PE20060648A1 (es)	2006-07-14	Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PE20011371A1 (es)	2002-01-18	Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
AR061374A1 (es)	2008-08-20	Derivados de diamidas de acido antranilico con sus sustituyentes heteroaromaticos y heterociclicos
PE20100138A1 (es)	2010-03-20	Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
CR20110013A (es)	2011-02-11	Derivados de Heteroarilo como Inhibidores de DGAT1
PE20190336A1 (es)	2019-03-07	Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20061442A1 (es)	2007-02-03	Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
PE20090813A1 (es)	2009-06-27	Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
AR074352A1 (es)	2011-01-12	Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica.
PE20081475A1 (es)	2008-10-18	Arilamidas sustituidas por tiazol u oxazol
PE20090226A1 (es)	2009-04-02	PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION
CL2003002665A1 (es)	2005-01-14	COMPUESTOS DERIVADOS DE ACIDOS CARBOXILICOS, SUS SALES; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DONDE ES NECESARIO UN INHIBIDORE DEL FACTOR Xa Y /O UN INHIBIDOR DE SERINA PROTEASA.
PE20091376A1 (es)	2009-09-25	Derivados de fenilamino como moduladores de beta-amiloide
PE20142019A1 (es)	2014-12-18	Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
AR060618A1 (es)	2008-07-02	Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo
PE20060736A1 (es)	2006-09-08	DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
PE20061298A1 (es)	2006-12-24	Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
PE20181197A1 (es)	2018-07-23	2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
PE20081345A1 (es)	2008-10-24	Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20061013A1 (es)	2006-10-13	Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
AR079260A1 (es)	2012-01-04	Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos
PE20120657A1 (es)	2012-06-27	Compuesto para el tratamiento de trastornos metabolicos

Legal Events

Date	Code	Title	Description
2011-10-28	FG	Grant, registration